CV Sciences Enters Material Definitive Agreement

TL;DR

CV Sciences signed a big deal, filing an 8-K on 10/10/25 about it.

AI Summary

CV Sciences, Inc. filed an 8-K on October 10, 2025, reporting on an event that occurred on October 7, 2025. The filing indicates the entry into a Material Definitive Agreement and includes financial statements and exhibits. The company, formerly known as CannaVEST Corp. and Foreclosure Solutions, Inc., is incorporated in Delaware and headquartered in San Diego, California.

Why It Matters

This filing signals a significant new contract or partnership for CV Sciences, which could impact its future business operations and financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, the specifics of which are not detailed in this initial 8-K filing.

Key Players & Entities

• CV Sciences, Inc. (company) — Registrant
• October 7, 2025 (date) — Date of earliest event reported
• October 10, 2025 (date) — Date of Report
• CannaVEST Corp. (company) — Former Company Name
• Foreclosure Solutions, Inc. (company) — Former Company Name
• Delaware (jurisdiction) — State of Incorporation
• San Diego, California (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $600,000 — ote in the original principal amount of $600,000 (the "Note"). The transaction closed on
• $150,000 — arries an original issuance discount of $150,000 which was deducted from the proceeds of
• $300,000 — t, the Company received net proceeds of $300,000 (the "Purchase Price"). In addition, th
• $13,125 — Price"). In addition, the Company paid $13,125 to the Investor to cover its legal and
• $46,153.85 — e investor starting on April 6, 2026 of $46,153.85. The Company can pay all or any portion

Filing Documents

• cvsi-20251007.htm (8-K) — 55KB
• cvsi-ex10_1.htm (EX-10.1) — 335KB
• cvsi-ex10_2.htm (EX-10.2) — 124KB
• cvsi-ex10_3.htm (EX-10.3) — 241KB
• cvsi-ex10_4.htm (EX-10.4) — 62KB
• 0001193125-25-237188.txt ( ) — 1021KB
• cvsi-20251007.xsd (EX-101.SCH) — 22KB
• cvsi-20251007_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement On October 6, 2025, CV Sciences, Inc., a Delaware corporation (the "Company") entered into a note purchase agreement ("Purchase Agreement") with an institutional investor ("Investor"), pursuant to which the Company issued and sold to the Investor a secured promissory note in the original principal amount of $600,000 (the "Note"). The transaction closed on October 7, 2025 ("Closing Date"). The Note carries an original issuance discount of $150,000 which was deducted from the proceeds of the Note received by the Company. In addition, the Company paid the Investor $150,000 associated with the modification of the original note purchase agreement ("Original Purchase Agreement") dated February 12, 2025, as modified on September 12, 2025. As a result, the Company received net proceeds of $300,000 (the "Purchase Price"). In addition, the Company paid $13,125 to the Investor to cover its legal and other fees. The unpaid amount of the Note, any interest, fees, charges and late fees accrued shall be due and payable on April 6, 2027 (the "Maturity Date"). The Company is required to make monthly repayments to the investor starting on April 6, 2026 of $46,153.85. The Company can pay all or any portion of the outstanding balance earlier than it is due without penalty. In the event the Company repays the Note in full on or before the six month anniversary of the Closing Date, the Company will receive a discount of 8% from the outstanding balance. The Note is secured by all of the Company's assets and assets of the Company's subsidiaries pursuant to a Security Agreement entered into with the Investor on October 6, 2025 (the "Security Agreement"). In addition, the Company and its subsidiaries entered into an Intellectual Property Security Agreement with the Investor pursuant to which the Company and its subsidiaries granted to the Investor a security interest in the Company's intellectual property. No additional interest will a

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits 10.1 Securities Purchase Agreement dated October 6, 2025 (confidential portions of the exhibit have been omitted where indicated) 10.2 Senior Secured Note due April 6, 2027 (confidential portions of the exhibit have been omitted where indicated) 10.3 Security Agreement dated October 6, 2025 (confidential portions of the exhibit have been omitted where indicated) 10.4 Intellectual Property Security Agreement dated October 6, 2025 (confidential portions of the exhibit have been omitted where indicated) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CV SCIENCES, INC. Date: October 10, 2025 By: /s/ Joseph Dowling Joseph Dowling Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR